Ready to Improve Your Biomarker Intelligence?

TALK TO A BIOMARKER STRATEGIST
Posts Currently viewing the category: "Biomarkers"

We have been working with Bio-Rad. As most of you know Bio-Rad provides the healthcare industry with innovative and useful products that help life science researchers accelerate the discovery process and medical diagnostic labs obtain faster, better results. They are one of the largest RUO and diagnostic providers in the world. Our partnership…(Read More)

We announced our new literature-focused features in our last blog post. One of the unique features of our approach is that we use deep learning concepts, a subset of machine learning, to text mine literature. A characteristic of deep learning is that various characteristics, or attributes, of a paper can be extracted. One of…(Read More)

We are excited to announce improvements to BiomarkerBase, increasing the coverage and analysis of literature. We’ve added biomarkers sourced only from literature, representing biomarkers in an earlier stage of development.  With this addition there are two main benefits: Access to biomarker and supporting information that is in an early stage of development (3x more…(Read More)

Yesterday we completed part 2 of our Safety Biomarkers and Pharmacovigilance webinar. We covered some great topics: The utility of safety biomarkers throughout the drug development process The regulatory framework for biomarker qualification Insight into how to identify biomarker information from the literature The role of biomarkers in post-marketing pharmacovigilance practices To view the…(Read More)

This week’s Chart of the Week demonstrates recent research on the correlation between the Biomarker Coverage Percent in a company’s pipeline and the Company’s Phase 3 Likelihood of Approval. This chart depicts how as a company increases their number of trials utilizing biomarkers, they will also see an increase in their likelihood…(Read More)

This week we introduced the correlation between a company’s biomarker coverage in their clinical trial pipeline and their Likelihood of Approval. After showing correlation between approval and biomarker use, we wanted to know more about a company’s biomarker use year over year. As we dove deeper into the use of biomarkers over the…(Read More)

We held a webinar on Tuesday that allowed us to introduce our Biomarker Intelligence Maturity Model and to announce our new partnership with AdisInsight, a member of the Springer Nature family. We can assure you that the two are related.  To see for yourself check out the webinar recording…(Read More)

Three weeks ago we introduced the concept of the Biomarker Intelligence Maturity Model where we unveiled the 5 stage, 4 swim-lane model representing how companies improve biomarker intelligence management to win in drug and diagnostic development. This is the second installment of that series where we will cover the Process swim lane. Specifically, we…(Read More)

This week’s Chart of the Week attempts to communicate recent research on the percent of results you are missing in your clinical information searches (e.g. pubmed, clinicaltrials.gov, etc) without utilizing  target and synonym technologies like in BiomarkerBase. This chart depicts how many relevant and potentially game changing trials and publications manual curation…(Read More)

This week’s Chart of the Week communicates recent research on the irrelevant results found through manual review of literature versus results found through a combination of human and machine curation. This preliminary research measures the percent decrease in curation time on Clinicaltrials.gov and Pubmed.com through utilization of BiomarkerBase and its ability to…(Read More)